BRPI0412581A - formulação dispersável de um agente antiinflamatório - Google Patents

formulação dispersável de um agente antiinflamatório

Info

Publication number
BRPI0412581A
BRPI0412581A BRPI0412581-9A BRPI0412581A BRPI0412581A BR PI0412581 A BRPI0412581 A BR PI0412581A BR PI0412581 A BRPI0412581 A BR PI0412581A BR PI0412581 A BRPI0412581 A BR PI0412581A
Authority
BR
Brazil
Prior art keywords
inflammatory agent
dispersible formulation
relates
formulation
organ
Prior art date
Application number
BRPI0412581-9A
Other languages
English (en)
Inventor
Nancy Jean Britten
Niki Ann Waldron
Jeffrey Lynn Watts
John Walter Hallberg
John William Ii Burns
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0412581A publication Critical patent/BRPI0412581A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçãO DISPERSáVEL DE UM AGENTE ANTIINFLAMATóRIO". A presente invenção refere-se a um método que é provido para o tratamento e/ou a prevenção de uma condição inflamatória em um órgão contendo fluido e que tenha um orifício natural para o exterior, tal como o úbere de um animal que produza leite, ou a orelha de um sujeito. A invenção também refere-se a uma composição farmacêutica dispersável adequada para infusão no órgão consoante o método da invenção, e a um processo para se preparar uma tal composição.
BRPI0412581-9A 2003-07-31 2004-07-19 formulação dispersável de um agente antiinflamatório BRPI0412581A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31
PCT/IB2004/002461 WO2005009436A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
BRPI0412581A true BRPI0412581A (pt) 2006-09-19

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412581-9A BRPI0412581A (pt) 2003-07-31 2004-07-19 formulação dispersável de um agente antiinflamatório

Country Status (14)

Country Link
EP (1) EP1651210A1 (pt)
JP (1) JP2007500691A (pt)
KR (1) KR100780983B1 (pt)
CN (1) CN1829510A (pt)
AU (1) AU2004258745A1 (pt)
BR (1) BRPI0412581A (pt)
CA (1) CA2533101A1 (pt)
CO (1) CO5650245A2 (pt)
IL (1) IL172735A0 (pt)
MX (1) MXPA06001288A (pt)
NO (1) NO20060982L (pt)
RU (1) RU2319508C2 (pt)
WO (1) WO2005009436A1 (pt)
ZA (1) ZA200600096B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (es) 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
RU2392929C2 (ru) * 2007-06-20 2010-06-27 Общество С Ограниченной Ответственностью "Гамаветфарм" Средство для стимуляции выброса стволовых кроветворных клеток в кровоток
UA111147C2 (uk) * 2009-11-11 2016-04-11 Байєр Б.В. Способи та композиції для лікування або профілактики зовнішнього отиту
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
EP2366408B1 (en) * 2010-03-01 2012-07-18 Laboratorios SALVAT, S.A. Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
CN102784161A (zh) * 2012-08-01 2012-11-21 张吉川 一种治疗急慢性中耳炎的特效滴耳液
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
HK1252531A1 (zh) 2015-08-05 2019-05-31 Children's Medical Center Corporation 用於药物递送的具有渗透增强剂的组合物
KR101738815B1 (ko) * 2015-08-27 2017-05-23 심민보 혈소판 풍부 혈장을 포함하는 감각신경성 난청 또는 이명을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
WO2019191547A1 (en) * 2018-03-29 2019-10-03 Yale University Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation
US20210308048A1 (en) * 2018-08-01 2021-10-07 Novilla Pharmaceuticals, Inc. Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак
KR102461699B1 (ko) * 2021-05-21 2022-11-03 현대약품 주식회사 벤지다민염산염을 포함하는 안정성이 개선된 가글액
KR20230084419A (ko) * 2021-12-03 2023-06-13 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
WO2023101421A1 (ko) * 2021-12-03 2023-06-08 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
JPH08511559A (ja) * 1993-06-18 1996-12-03 スミスクライン・ビーチャム・コーポレイション 軟外皮ゼラチンに封入された粒子
CN100335063C (zh) * 1994-10-26 2007-09-05 诺瓦蒂斯有限公司 药物组合物
NZ309624A (en) * 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US20020188016A9 (en) * 2000-06-08 2002-12-12 Peterson Johnny W. Heterocycle derivatives and methods of use
BR0111718A (pt) * 2000-06-16 2003-09-09 Hercules Inc Peptìdeos quimicamente modificados, composições e métodos de produção e uso
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
MXPA03002056A (es) * 2000-09-12 2003-07-24 Pharmacia & Upjohn Company Composicion farmaceutica con actividad de agua especifica.
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
KR20060031873A (ko) 2006-04-13
WO2005009436A1 (en) 2005-02-03
NO20060982L (no) 2006-05-02
JP2007500691A (ja) 2007-01-18
WO2005009436A8 (en) 2005-05-06
CA2533101A1 (en) 2005-02-03
RU2006101628A (ru) 2006-08-27
MXPA06001288A (es) 2006-04-11
CO5650245A2 (es) 2006-06-30
CN1829510A (zh) 2006-09-06
RU2319508C2 (ru) 2008-03-20
AU2004258745A1 (en) 2005-02-03
ZA200600096B (en) 2007-02-28
IL172735A0 (en) 2006-04-10
EP1651210A1 (en) 2006-05-03
KR100780983B1 (ko) 2007-11-30

Similar Documents

Publication Publication Date Title
BRPI0412581A (pt) formulação dispersável de um agente antiinflamatório
BRPI0408559A (pt) composições farmacêuticas dispersìveis para o tratamento de mastite e distúrbios óticos
BRPI0408556A (pt) formulações dispersìvel de um agente antiinflamatório
BRPI0414320A (pt) composição para tratamento da pele
CL2009000555A1 (es) Compuestos derivados de tetramatos sustituidos espirociclicamente con 4'4'-dioxaespiro; procedimiento de preparacion; agente para combatir plagas y/o vegetaciones indeseadas que comprende dichos compuestos; su procedimiento de preparacion y uso; composiciones y su uso
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
BRPI0108449B8 (pt) formulações de pasta aperfeiçoada, suas aplicações farmacêuticas, método para matar insetos, bem como processo para preparar as referidas formulações
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BRPI0512583A (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
AR029462A1 (es) Derivados del acido picolinico, procedimiento para prepararlos y composiciones formuladas con dichos derivados como agente activo, procedimientos preventivos o curativos contra hongos fitopatogenos, metodos preventivos o de tratamiento de la madera para la construccion utilizando dichos compuestos y
BRPI0410795A (pt) composições para tratamento de infecção em bovinos e suìnos
BRPI0618374A2 (pt) uso de um composto ou um derivado do mesmo farmaceuticamente aceitável, métodos para matar microorganismos clinicamente latentes em um mamìfero, para tratar ou prevenir uma infecção microbiana em um mamìfero, para esterilizar um objeto, para preservar um material inorgánico ou orgánico, para tratar uma doença, para reduzir a dose de agente antimicrobiano convencional requerida para tratar uma infecção microbiana e para tratar uma doença de protozoário em um mamìfero, produto combinado, formulação, uso de um produto combinado, composto, e, processo para a preparação do mesmo
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
SE8600501D0 (sv) Preparat for behandling av nagelsvamp och seborroiskt eksem
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
MX2007012730A (es) Composiciones para el cuidado personal que comprenden resinas de silicon con propiedades mejoradas, metodo de manufactura y metodo para usar las mismas.
BRPI0516077A (pt) composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes
US20080299233A1 (en) Method and composition for treating ear inflammation caused by dry ear
PE20050893A1 (es) Composicion bioinmune-agresina para la supresion de infecciones por xantomonas fitopatogenas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.